Email this article 
Post a Comment EARLY BREAST CANCER. THE CONTROVERSY OF BREAST CANCER IN SITU
- Authors: Kosyi VV1, Kedrova AG1
-
Affiliations:
- ФНКЦ ФМБА России
- Issue: Vol 6, No 2 (2015)
- Pages: 60-65
- Section: Articles
- URL: https://journals.rcsi.science/clinpractice/article/view/8333
- DOI: https://doi.org/10.17816/clinpract6260-65
- ID: 8333
Cite item
Full Text
Abstract
Perfecting screening tests of breast cancer by introducing digital mammography has increased findings the initial stages of the growth (neoplasma) in situ up to 25% of all detected cases of breast cancer. It has lead to 98% of surgical or combined forms of treatment although the risk of the advance into intrusive cancer is observed only in 50% to 75% of patients. In this connection the search for the prognosis marker and the degree of the radicalism of the treatment of such patients is the most discussed questions on clinic forums. This article discusses the re-thinking of the problem of the initial stages of breast cancer and working-out the best possible approach to its treatment.
Full Text
##article.viewOnOriginalSite##About the authors
V V Kosyi
ФНКЦ ФМБА Россииврач-онколог онкологического отделения ФНКЦ ФМБА
A G Kedrova
ФНКЦ ФМБА России
Email: kedrova.anna@gmail.com
д.м.н., профессор, зав. онкологическим отделением ФНКЦ ФМБА России
References
- Nekhlyudov L, Habel LA, Achacoso N, et al. Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. J Natl Cancer Inst. 2012;104: 614-621
- Cancer facts and figures 2015. Breast Carcinoma In situ. 2015. Atlanta: American Cancer Society; 2015. pp.26-37
- Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ [published online August 20, 2015]. JAMA Oncol. doi: 10.1001/jamaoncol.2015.2510.
- Cuzick J, Sestak I, Cawthorn S, et al; IBIS-I Investigators. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67-75.
- Morrow M., Schnitt Stuart J., Norton L. //Current management of lesions associated with an increased risk of breast cancer. Nat Rev Clin Oncol. 2015, 12, 237-8.
- Provenzano E, Hopper JL, Giles GG et al. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 2003; 39: 622-30.
- Lari SA, Kuerer HM. Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review. J Cancer 2011; 2: 232-261
- Solin L, Gray R, Baehner FL, Butler S et al. A prospective validation study of the DCIS score from ECOG E5194. Cancer Res 2011; 71: 41.
- Lee H.S. Use of Immunohistochemistry in the Diagnosis of Problematic Breast Lesions. J Clin Pathol. 2013;66(6):471-477.
- Barnes, A. Cramer, R. Johnson, K.Cheema, et al. Bundred Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Onc 2015 May 1; 26(5): 1019 -25.
- Esserman L., Yau C., Rethinking the Standard for Ductal Carcinoma In Situ Treatment. JAMA Oncol. 2015 DOI: 10,1001 / jamaoncol.2015.2607.
- Guillot E, Vaysse C, Goetgeluck J, Falcou M.C., Extensive pure ductal carcinoma in situ of the breast: identification of predictors of associated infiltrating carcinoma and lymph node metastasis before immediate reconstructive surgery. Breast. 2014 Apr;23(2):97-103. doi: 10.1016/j.breast.2013.12.002.
- American Cancer Society. Lifetime risk of developing or dying from cancer. Revised October 1, 2014. http://www.cancer.org/cancer/cancerbasics/lifetime-probability-of-developing-or-dying-from-cancer. Accessed June 25, 2015.
- Luo J, Cochrane BB, Wactawski-Wende J, Hunt JR, Ockene JK, Margolis KL. Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2013;137: 915-925
- Margolese RG, Cecchini RS, Julian TB, et al. Primary results, NRG Oncology/NSABP B-35: a clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. Am Soc Clin Oncol. 2015;33(suppl):abstr LBA500
- Correa C, McGale P, Taylor C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010: 162-177.
- National Comprehensive Cancer Network. Breast Cancer (Version 3.2014 October,2014). Available from URL www.nccn.org/professionals/ physician_gls/pdf/breast.pdf
- Rakovitch E., Nofech-Mozes S., Hanna W., et.al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Research and Treatment, July 2015, Volume 152, Issue 2, pp 389-398.
- Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-98
- Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382-87.
- Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003;56: 1038-45.
- Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57: 75-89
- Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009; 27: 1362-1367
- Pieri A, Harvey J, Bundred N. Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guidepractice? World J of Clin Onco. 2014;5: 546-553
- Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of Surveillance, Epidemiology, and End Results data. J Clin Oncol. 2005;23: 5534-5541
- Portschy PR, Marmor S, Nzara R, Virnig BA, Tuttle TM. Trends in incidence and management of lobular carcinoma in situ: a populationbased analysis. Ann Surg Oncol. 2013;20: 3240-46.
- Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57: 75-89.
- Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30: 1268-73.
